- Home
- DNTH vs EQBK Comparison
DNTH vs EQBK Comparison
Compare DNTH & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- EQBK
- Stock Information
- Founded
- DNTH 2015
- EQBK 2002
- Country
- DNTH United States
- EQBK United States
- Employees
- DNTH N/A
- EQBK N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- EQBK Major Banks
- Sector
- DNTH Health Care
- EQBK Finance
- Exchange
- DNTH Nasdaq
- EQBK Nasdaq
- Market Cap
- DNTH 670.7M
- EQBK 763.9M
- IPO Year
- DNTH N/A
- EQBK 2015
- Fundamental
- Price
- DNTH $22.29
- EQBK $44.14
- Analyst Decision
- DNTH Strong Buy
- EQBK Hold
- Analyst Count
- DNTH 9
- EQBK 5
- Target Price
- DNTH $46.43
- EQBK $45.60
- AVG Volume (30 Days)
- DNTH 245.5K
- EQBK 72.0K
- Earning Date
- DNTH 03-20-2025
- EQBK 01-22-2025
- Dividend Yield
- DNTH N/A
- EQBK 1.40%
- EPS Growth
- DNTH N/A
- EQBK 700.00
- EPS
- DNTH N/A
- EQBK 4.00
- Revenue
- DNTH $5,366,000.00
- EQBK $220,307,000.00
- Revenue This Year
- DNTH $100.14
- EQBK N/A
- Revenue Next Year
- DNTH N/A
- EQBK $6.19
- P/E Ratio
- DNTH N/A
- EQBK $10.75
- Revenue Growth
- DNTH 51.41
- EQBK 59.51
- 52 Week Low
- DNTH $18.35
- EQBK $30.44
- 52 Week High
- DNTH $33.77
- EQBK $50.85
- Technical
- Relative Strength Index (RSI)
- DNTH 49.77
- EQBK 47.15
- Support Level
- DNTH $21.28
- EQBK $43.47
- Resistance Level
- DNTH $23.28
- EQBK $44.66
- Average True Range (ATR)
- DNTH 1.75
- EQBK 1.02
- MACD
- DNTH 0.17
- EQBK 0.21
- Stochastic Oscillator
- DNTH 79.92
- EQBK 57.76
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. The company's operation involves the delivery of loan and deposit products to customers. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.